Why You Should Know About the R56 Funding Mechanism

By Bouvier Grant Group

We stay current on NIH happenings and would be delighted to keep you informed.

Many researchers are not aware of the NIH R56 funding mechanism. Its goal is to provide 1-2 years of funding to promising submissions that are outside the funding range, with the ultimate goal of putting in a more competitive R01 at the end of the R56 funding period. A few important things to know about the R56:

  • It is available to R01 applicants only.
  • You may not apply directly. The recipients are typically chosen by program staff. Need I continue to beat my “get to know your program officer” drum? Please, please develop a relationship with your NIH PO whenever possible. They are more important to your career than you think, in many ways.
  • Applications chosen are not necessarily just outside the funding range. While the description of the award does state it is for “R01 applications with priority scores or percentiles that fall just outside the funding limits”, it goes on to state that “Nominees for the award must be in the most meritorious half of the priority or percentile range” (i.e., not triaged). Of the few clients I know who have been selected for an R56 over the years, in one memorable instance the grantee had an R01 ranked 30%, but the PO knew him well and strongly believed in his work (see “get to know your PO” above).

The NIA, NIAID, NCI, NHLBI, and several other I&Cs participate in the R56 and are listed on the NIH page.

Dr. Meg Bouvier

Author:
Dr. Meg Bouvier

Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015. She's recently worked with more than 40% of the nation's highest-performing hospitals*, four of the top 10 cancer hospitals, three of the top five medical schools for research, and 14 NCI-designated cancer centers. Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.

*Our clients include 9 of the top 22 hospitals as recognized by the 2023/24 US News & World Report honor roll

Categories:
Related posts

You May Also Be Interested In

Bouvier Grant Group logo white
We read all NIH notices for our clients. When you join our mailing list, we’ll pass along important changes directly to your inbox, as well as opportunities to improve your grantsmanship skills.
Primary Position
Lead Source

Wait!

Subscribe to our monthly newsletter for the latest NIH news, grantwriting tips, and more.

NIH October 2023 Newsletter cover